NCT07372651

Brief Summary

Pacemakers are an effective treatment for slow heart rates which improve symptoms and save lives. However, for some people pacemakers can cause heart failure (HF) because of the unnatural way in which they stimulate heart beats. In several studies conducted in West Yorkshire we showed that \~1/3 of patients with pacemakers have undiagnosed HF. We also showed that where HF is discovered, treating it with safe and inexpensive medications reduces the chances of being admitted to hospital or dying. However, detecting HF requires an echocardiogram (a heart ultrasound scan) which takes \~45 minutes, requires a skilled technician, and costs £120; or, to put it another way \~£540,000 to assess the \~4,500 patients cared for at our hospital. A new approach is needed. We think that using new technologies can improve our ability to screen for HF in people with pacemakers. We will test two approaches. First, we will assess whether a hand-held echocardiogram can measure heart function using artificial intelligence (AI) as accurately as a standard echocardiogram done by a skilled technician. Second, we will assess whether a finger-prick blood test can detect the presence of abnormal function as accurately as a standard echocardiogram.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
4mo left

Started Oct 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress65%
Oct 2025Sep 2026

First Submitted

Initial submission to the registry

September 29, 2025

Completed
8 days until next milestone

Study Start

First participant enrolled

October 7, 2025

Completed
4 months until next milestone

First Posted

Study publicly available on registry

January 28, 2026

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2026

Last Updated

January 28, 2026

Status Verified

January 1, 2026

Enrollment Period

11 months

First QC Date

September 29, 2025

Last Update Submit

January 19, 2026

Conditions

Keywords

Heart failureArtificial intelligencePacemaker

Outcome Measures

Primary Outcomes (1)

  • The accuracy of artificial intelligence derived left ventricular ejection fraction (LVEF) compared to expert sonographer measured LVEF

    Determined by the individual equivalence coefficient of artificial intelligence (AI) derived left ventricular ejection fraction (LVEF) versus to sonographer measured LVEF. The accuracy of AI LVEF will be compared to sonographer measured LVEF for non-inferiority. The pre-determined non-inferiority margin is 0.25 for the upper bound of the 95% confidence interval for this comparison.

    Day 1

Secondary Outcomes (3)

  • Accuracy of artificial intelligence derived left ventricular ejection fraction of <50%

    Day 1

  • Prediction of left ventricular ejection fraction <50%

    Day 1

  • The utility of artificial intelligence echocardiography

    Day 1

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with previously implanted pacemakers for bradycardia.

You may qualify if:

  • Adult patients aged ≥18 years
  • Patients with existing pacemakers who have a right ventricular pacing burden ≥20%.
  • Ability to provide informed consent

You may not qualify if:

  • Patients who are unwilling or unable to provide informed consent.
  • Patients known to have heart failure
  • Patients with any previous measurement of left ventricular ejection fraction \<50%.
  • Patients with conduction system pacemakers.
  • Patients with cardiac resynchronisation therapy pacemakers/defibrillators.
  • Patients with implantable cardioverter defibrillators.
  • Patients with leadless pacemakers.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cardiovascular Research Facility, Leeds General Infirmary

Leeds, LS1 3EX, United Kingdom

Location

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Lecturer in Cardiology

Study Record Dates

First Submitted

September 29, 2025

First Posted

January 28, 2026

Study Start

October 7, 2025

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

September 1, 2026

Last Updated

January 28, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

Locations